BioTech Drug Development Strategy 
Healthcare IT Today
JANUARY 23, 2024
Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients. Petra Jantzer, Ph.D.,
Digital Health Global
MARCH 2, 2023
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development. For more information on SSI Strategy, please visit www.ssistrategy.com.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Society for Participatory Medicine
FEBRUARY 1, 2023
The FDA issued a series of four patient-focused drug development (PFDD) guidance documents which outline how patient co-design needs to successfully happen. After all of this time and energy expended, it’s only right that patients would be witness to accountability of pharma/biotech to incorporate our collective voice.
Digital Health Global
NOVEMBER 30, 2023
Furthermore, by fostering connectivity and automating tasks, DHTs reduce administrative burdens, accelerate recruitment, and improve overall trial transparency, ultimately contributing to faster and more reliable drug development.
Digital Health Global
APRIL 25, 2024
About Koneksa Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. Koneksa aims to revolutionize treatment effect detection in clinical research and improve patient outcomes.
Digital Health Global
AUGUST 30, 2023
QuantHealth bridges these gaps by simulating trials at scale, to expedite, derisk, and optimize drug development. QuantHealth proudly supports several large pharma companies, numerous biotechs, as well as CROs, and other industry partners.
Healthcare IT Today
JANUARY 8, 2024
Now, they have new tools such as artificial intelligence (AI) and machine learning (ML) that they can leverage to automatically scour medical literature for information to assist signal evaluation and medical review, or real-world-evidence insights that can lead to drug-safety improvements. Dave Latshaw, CEO at BioPhy 1.
Expert insights. Personalized for you.
122 
Let's personalize your content